This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|April 19, 2021
CordenPharma to Expand Lipid Purification Capacity at its Colorado Site
Author(s)BioPharm International Editors
CordenPharma’s expansion will include the addition of new production lines which will be merged into the lipid manufacturing process in April 2021.
Advertisement
CordenPharma announced on April 19, 2021 that it is expanding its lipid purification capacity at its Colorado site.
According to a CordenPharma press release, the expansion will include the addition of new production lines, which will be merged into the lipid manufacturing process in April 2021. By July 2021, the company expects a decrease in lipid shipment delivery time due to the expansion.
“CordenPharma is proud to contribute this major capital expansion to increase important lipid production for the global market,” said Michael Quirmbach, CEO and president, CordenPharma. “We have drawn upon longstanding expertise in specialized lipids to create an even stronger integrated network of facilities to support current and future projects.”
The company, who has also expanded its lipid supply chain at its facilities in Switzerland and France, manufactures four lipids used to formulate messenger RNA (mRNA)-based vaccines. They include:
- Cationic lipids that condense negatively charged mRNA
- PEGylated lipids that form a protective hydrophilic layer, which sterically stabilizes the lipid nanoparticle (LNP)
- DiStearoylphosPhatidylCholine (DSPC), a phospholipid that offers a stable bilayer-forming structure
- Plant-based cholesterol (CP BotaniChol), which stabilizes the LNP structures and enables endosome escape.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5